# Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

> **NCT00053248** · PHASE1,PHASE2 · COMPLETED · sponsor: **OHSU Knight Cancer Institute** · enrollment: 16 (actual)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** arsenic trioxide
- **DRUG:** imatinib mesylate

## Key facts

- **NCT ID:** NCT00053248
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-10
- **Primary completion:** 2005-06
- **Final completion:** 2005-06
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2012-05-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00053248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00053248, "Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00053248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*